Inovio has now completed cGMP clinical product manufacturing of its H1N1 SynCon?„? vaccine candidate, an important step in advancing the candidate toward clinical testing. As part of the company ™s strategy for its universal influenza vaccine, the H1N1 vaccine would be combined with Inovio ™s H5N1 vaccine candidate, for which an IND has already been submitted to the FDA. On the path toward its universal influenza vaccine concept, Inovio will also mix in constructs for H2N2 and H3N2 influenza sub-types; together these four sub-types were responsible for most of the seasonal and pandemic influenza outbreaks of the last 100 years.

Dr. Kim also described the company ™s recently reported results for its therapeutic HPV/cervical cancer DNA vaccine. Inovio reported significant T-cell responses in 50% (3 of 6) and strong antibody responses in 83% (5 of 6) subjects treated with just the first, low-dose group in its phase I clinical study. Generating a significant T-cell immune response is considered imperative to treating cancers and infectious diseases such as HIV and hepatitis C virus. The T-cell immune responses generated in this study were among the strongest generated by a DNA vaccine in humans.

inovio/